Overview
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody mediated rejection. The study hypothesizes that blood gene expression profile and donor-derived cell-free DNA biomarkers (omnigraf) can be used to predict acute rejection and monitor its response to treatment.
Eligibility
Inclusion Criteria:
- Kidney transplant recipients
- Participants undergoing a for-cause kidney biopsy to rule out graft rejection
- Ages 21 years and less
Exclusion Criteria:
- Participants who have opted out of research
- Patients, less than 18 years of age, whose parents or legal guardians are illiterate and cannot read.
- Participants, 18 years and older, who are illiterate and cannot read.
- Participants, less than 18 years of age, whose parents or legal guardians do not speak English.
- Participants, 18 years and older, who do not speak English
- Participants who are pregnant as confirmed by medical records